Prognostic role of HER2 expression in bladder cancer: a systematic review and meta-analysis
- PMID: 25384433
- DOI: 10.1007/s11255-014-0866-z
Prognostic role of HER2 expression in bladder cancer: a systematic review and meta-analysis
Abstract
Objective: The prognostic role of human epidermal growth factor receptor 2 (HER2) in bladder cancer (BCa) remains controversial. Thus, we conducted a meta-analysis to assess the prognostic significance of HER2 for patients with BCa.
Materials and methods: Systematically computerised searching in PubMed, Scopus database, Embase and Cochrane Library Database was conducted. Published studies comparing the prognosis in patients with BCa stratified by HER2 status were included, and relationships between HER2 positivity and gender, stage, grade, lymph node metastasis and survival were analysed.
Results: Nine studies with 2,242 eligible patients were identified. HER2 expression was significantly correlated with poor disease-specific survival [pooled hazard ratio (HR) 2.00; 95% confidence interval (CI) 1.22-3.29; P=0.006] and disease-free survival (pooled HR 1.68; 95% CI 1.33-2.14; P<0.0001) of patients with BCa. The positive rates of HER2 ranged from 27.8 to 85.2% with a pooled positive rate of 41.2% (1,006/2,442). HER2 expression was significantly associated with tumour grade [high grade vs. low grade: odds ratio (OR) 4.08; 95% CI 1.29-12.93] and lymph node metastasis (positive vs. negative: OR 1.71; 95% CI 1.07-2.75).
Conclusions: This meta-analysis indicated that HER2 expression is associated with poor prognosis. Thus, HER2 could serve as a useful biomarker for clinical prediction.
Similar articles
-
A systematic review and meta-analysis for human epidermal growth factor receptor 2 on upper tract urothelial carcinoma patients.Tumori. 2024 Feb;110(1):25-33. doi: 10.1177/03008916231186178. Epub 2023 Aug 9. Tumori. 2024. PMID: 37555322 Review.
-
Prognostic and clinicopathological value of Twist expression in breast cancer: A meta-analysis.PLoS One. 2017 Oct 9;12(10):e0186191. doi: 10.1371/journal.pone.0186191. eCollection 2017. PLoS One. 2017. PMID: 29016671 Free PMC article.
-
The effect of HER2 status on oncological outcomes of patients with invasive bladder cancer.Urol Oncol. 2016 Dec;34(12):533.e1-533.e10. doi: 10.1016/j.urolonc.2016.07.006. Epub 2016 Sep 21. Urol Oncol. 2016. PMID: 27665356
-
TIF1γ interferes with TGFβ1/SMAD4 signaling to promote poor outcome in operable breast cancer patients.BMC Cancer. 2015 Jun 4;15:453. doi: 10.1186/s12885-015-1471-y. BMC Cancer. 2015. PMID: 26040677 Free PMC article.
-
Lymph node density as a prognostic variable in node-positive bladder cancer: a meta-analysis.BMC Cancer. 2015 Jun 2;15:447. doi: 10.1186/s12885-015-1448-x. BMC Cancer. 2015. PMID: 26027955 Free PMC article. Review.
Cited by
-
Expression of HER2 in high-grade urothelial carcinoma based on Chinese expert consensus and the clinical effects of disitamab vedotin-tislelizumab combination therapy in the treatment of advanced patients.Front Pharmacol. 2024 Feb 22;15:1355081. doi: 10.3389/fphar.2024.1355081. eCollection 2024. Front Pharmacol. 2024. PMID: 38455962 Free PMC article.
-
RC48-ADC combined with tislelizumab as neoadjuvant treatment in patients with HER2-positive locally advanced muscle-invasive urothelial bladder cancer: a multi-center phase Ib/II study (HOPE-03).Front Oncol. 2024 Jan 10;13:1233196. doi: 10.3389/fonc.2023.1233196. eCollection 2023. Front Oncol. 2024. PMID: 38269021 Free PMC article.
-
Molecular Targeting of the Human Epidermal Growth Factor Receptor-2 (HER2) Genes across Various Cancers.Int J Mol Sci. 2024 Jan 15;25(2):1064. doi: 10.3390/ijms25021064. Int J Mol Sci. 2024. PMID: 38256137 Free PMC article. Review.
-
Frequency of next-generation sequencing, prevalence of targetable mutations and response to targeted therapies amongst patients with metastatic urothelial cancer in Ireland: a multi-centre retrospective study of real-world data.Ir J Med Sci. 2024 Jun;193(3):1155-1161. doi: 10.1007/s11845-023-03569-2. Epub 2023 Nov 10. Ir J Med Sci. 2024. PMID: 37947995
-
ERBB2 Amplification as a Predictive and Prognostic Biomarker in Upper Tract Urothelial Carcinoma.Cancers (Basel). 2023 Apr 22;15(9):2414. doi: 10.3390/cancers15092414. Cancers (Basel). 2023. PMID: 37173881 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous